Melphalan Weight-Based Dosing in Overweight and Obese Patients Undergoing Autologous Transplant for Multiple Myeloma

Key Points

• Weight-based melphalan dosing leads to significant improvement in treatment outcomes for obese multiple myeloma patients undergoing autologous transplants.
• The analysis shows that using body weight to calculate melphalan doses has a measurable impact on patient responses post-transplant, particularly in obese populations.
• Assessment of pharmacokinetics for melphalan dosing reveals variabilities that can affect treatment efficacy in higher body mass indices.
• The findings indicate that adjusting dosing strategies could optimize treatment outcomes, highlighting the need for individualized approaches in chemotherapy.